Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Conventional Ultrasound for Imaging of Prostate Cancer Extent and Response in Human Cancer Patients

This study is currently recruiting participants. (see Contacts and Locations)
Verified May 2017 by Sunnybrook Health Sciences Centre
Information provided by (Responsible Party):
Dr. Gregory Czarnota, Sunnybrook Health Sciences Centre Identifier:
First received: September 1, 2010
Last updated: May 1, 2017
Last verified: May 2017
In this observational study the investigators will undertake imaging studies on men with prostate cancer. The primary hypothesis is that ultrasound spectroscopy could be used to determine the extent of disease inside and outside of the prostate gland in patients with prostate cancer. It is hoped that the changes in ultrasound backscatter parameters obtained before radical prostatectomy could be used to correlate with pathological findings from the prostate specimen after surgery.

Prostate Cancer

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Conventional and Contrast-Assisted Frequency Functional Ultrasound for Imaging of Prostate Cancer Extent and Response in Human Cancer Patients

Resource links provided by NLM:

Further study details as provided by Sunnybrook Health Sciences Centre:

Primary Outcome Measures:
  • ultrasound backscatter parameters such as aggregate mid-band fit, spectroscopic slope and intercept and the number of vessels with detectable blood flow and their sizes [ Time Frame: Up to year 2019 ]
    These parameters will be obtained before radical prostatectomy to correlate with pathological findings from the prostate specimen after surgery.

Secondary Outcome Measures:
  • sensitivity and specificity of ultrasound-based imaging of the prostate [ Time Frame: Up to year 2019 ]
    the changes in the ultrasound backscatter parameters obtained from the ultrasonic spectroscopy during patient's radiation treatment would be used to monitor tumor response and to correlate with pathological findings in patients with prostate cancer.

Biospecimen Retention:   Samples With DNA
Prostate speciments are retained after radical prostatectomy surgery

Estimated Enrollment: 10
Study Start Date: September 2008
Estimated Study Completion Date: September 2018
Estimated Primary Completion Date: September 2018 (Final data collection date for primary outcome measure)
Detailed Description:

This project is an early validation study in human subjects that will use ultrasound imaging and spectroscopy to predict the tumour extent before treatment so that this may allow the most appropriate treatment intervention to be individualised to patients. For examples, patients with evidence of extra-prostatic tissue involvement may be best served with definitive radiation therapy rather than radical prostatectomy as surgery alone in this situation, is not optimum. Furthermore, these ultrasound parameters may be used to monitor cell death occurring at various time points during patients' radiation treatment for prostate cancer.

The research is exploratory since upon data analysis it will examine the use of different ultrasound parameters as potential markers of pre-treatment tumour extent and cell death, and correlate these with tumour shrinkage and complete pathological response. Sensitivity and specificity values for the various ultrasound parameters will be calculated for the different time points used and receiver-operator curves will be generated. From this data the investigators will potentially estimate the best time-points at which to make a prediction about patient response and the best ultrasound-spectroscopy variables to use for this purpose.


Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
The study will investigate a population of 30 men with prostate cancer undergoing radical prostatectomy surgery.

Inclusion Criteria:

  • Prostate Cancer

Exclusion Criteria:

  • Not having radical prostatectomy surgery
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01401972

Contact: Gregory J. Czarnota (416) 480-6100 ext 7073
Contact: William T. Tran (416) 480-6100 ext 1099

Canada, Ontario
Sunnybrook Health Sciences Centre Recruiting
Toronto, Ontario, Canada, M4N 3M5
Contact: Gregory Czarnota, PhD, M.D.    (416) 480-6100 ext 7073   
Sponsors and Collaborators
Sunnybrook Health Sciences Centre
Principal Investigator: Gregory Czarnota, PhD, M.D. Sunnybrook Health Sciences Centre
  More Information

Responsible Party: Dr. Gregory Czarnota, Dr., Sunnybrook Health Sciences Centre Identifier: NCT01401972     History of Changes
Other Study ID Numbers: Ultrasound Prostate Cancer
Study First Received: September 1, 2010
Last Updated: May 1, 2017

Keywords provided by Sunnybrook Health Sciences Centre:

Additional relevant MeSH terms:
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Genital Diseases, Male
Prostatic Diseases processed this record on May 24, 2017